Las Vegas, NV -- (SBWIRE) -- 12/30/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more. EquityObserver.com issues a special report on the following stocks:Generex Biotechnology Corporation(OTCMKTS:GNBT),Catalyst Pharmaceutical Partners, Inc.(NASDAQ:CPRX),RadioShack Corporation(NYSE:RSH),Rigel Pharmaceuticals, Inc.(NASDAQ:RIGL)
Generex Biotechnology Corporation(OTCMKTS:GNBT)managed to keep its common at 0.00% on below-normal volume of 1.53Mshares. The stock settled at $0.0290, after floating in a range of $0.03 - 0.03. Its latest price has reached market capitalization of $16.83M. Its 52-week range has been $0.02 - 0.07. Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes.
How Should Investors Trade GNBT Now?Don’t Miss out a Special Trend Analysis
Catalyst Pharmaceutical Partners, Inc.(NASDAQ:CPRX)trading on a volume of 1.51Mshares, higher than its standard daily volume. Shares have been closed at $2.10. Over the last twelve months, the stock has gained382.75% and faced a worst price of $0.41.Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company.
Is CPRX a Solid Investment at These Levels?Read This Report for Details
RadioShack Corporation(NYSE:RSH)is up at $2.67 on below- normal volume of 1.48Mshares during the last trading day. The stock has its 12-month range $2.05 - 4.36. Its Intraday range is $2.60 - 2.71.RadioShack Corporation (RadioShack) is engaged in the retail sale of consumer electronics goods and services through its RadioShack store chain.
How Should Investors Trade RSH Now?Don’t Miss out a Special Trend Analysis
In the last trading day, Rigel Pharmaceuticals, Inc.(NASDAQ:RIGL)is on high volume, trading at a volume of versus its average daily volume ratio 1.46M/1.09Mshares. At $2.74, the stock has attained market capitalization of 239.56M.Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company.
Will Investors Buy RIGL After Reading This News?Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)